Announcements Trials
Browse Landscape

Phase

Phase NA 12Phase 2 3Phase 1 3Phase 3 2Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 2Other solid neoplasm 1Other 1Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Recurrence 1

Interventions

Carboplatin 66Paclitaxel 54pembrolizumab 49Cyclophosphamide 34Cisplatin 28Bevacizumab 26Nivolumab 21Gemcitabine 18fludarabine 17liposomal doxorubicin 15Topotecan 15aldesleukin 13Filgrastim 12olaparib 11Interleukin-2 11Docetaxel 11Peripheral Blood Stem Cell Transplantation 10durvalumab 9Taxes 9Specimen Handling 9Oxaliplatin 8fludarabine phosphate 7epacadostat 7Magnetic Resonance Spectroscopy 7Ipilimumab 7Injections 7rucaparib 6niraparib 6lenvatinib 6cemiplimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Therapeutics × Gynecologic × Clear all
NCT07542717 2026-04-21

ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1/2 Not yet recruiting
41 enrolled
Gynecologic

Uterine Cervical Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡